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Abstract
Purpose The purpose of this study was to test the ability of
DAC®, a fast resorbable, antibacterial-loaded hydrogel coating,
to prevent acute bacterial colonization in an in vivomodel of an
intra-operatively highly contaminated implant.
Methods A histocompatibility study was performed in 10
adult New Zealand rabbits. Then, methicillin-resistant Staph.
aureus were inoculated in the femur of 30 adult New Zealand
rabbits at the time of intra-medullary nailing; vancomycin-
loaded DAC® coated nails were compared to controls regard-
ing local and systemic infection development.
Results Histocompatibility study showed no detrimental effect
of DAC® hydrogel on bone tissue after 12 weeks from implant.
After seven days from implant, none of the rabbits receiving
vancomycin-loaded DAC® nail showed positive blood cultures,
compared to all the controls; vancomycin-loaded DAC®
coating was associated with local bacterial load reduction
ranging from 72 to 99 %, compared to controls.
Conclusions Vancomycin-loaded DAC® coating is able to
significantly reduce bacterial colonization in an animal model
of an intra-operatively highly contaminated implant, without
local or general side effect.
Keywords Infection . Implant . Coating . Nail . Prosthesis .
Hydrogel . DAC
Introduction
Post-surgical infections represent a common healthcare prob-
lem, with Staphylococci being the leading micro-organism
involved [1, 2].
According to the latest Annual Epidemiological Report
drawn in 2012 by the European Centre for Disease and Con-
trol, a successful control has been performed, and especially
Methicillin-resistant Staphylococcus aureus (MRSA) isola-
tion appears stable or decreasing in many European Countries
[3]. Nevertheless, in some of them, the percentage of MRSA
isolation is above 25 %, suggesting how neither the wide
range of antimicrobial agents nor the best clinical prophylaxis
in the operating room led to a complete surgical infection
control and eradication. Concerning the orthopedic field, the
issue posed by bacterial infection is considerable, especially
because MRSA is among the most frequently reported agent
associated with orthopaedic implant infection [4].
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In situations in which an inert foreign body is implanted into
an already injured and weakened tissue, a competition develops
for the colonization of the implant surface between bacteria and
the cells of the immune system. However, bacteria have the
advantage over immune system cells of faster reproductive
processes and an extreme flexibility in adapting to the environ-
ment [5]. While infection after primary joint replacement in
normal hosts is relatively rare, occurring in less than 2 % of the
patients, septic complications may be much more frequent in
immunocompromised hosts or after revision or contaminated
surgery [6]. In spite of the relatively low incidence of post-
surgical septic complications, their overall socio-economic bur-
den is going to increase, due to various factors [7].
Different treatment strategies can be adopted to counteract
orthopaedic infections, depending on overall patient conditions
(immune system, joint status and its functionality, etc.) and
according to involved pathogens and infection severity [8].
According to widely available data, local antibiotic delivery
represents an effective strategy to prevent and even to treat bone
infections [9–12]. Polymethyl-methacrylate (PMMA) bone ce-
ment has probably been the most widely adopted material to
locally release antibiotic, although it may have some draw-
backs, including its non-biodegradability, possible microbial
adhesion and biofilm formation, restricted range of loadable
antibiotics and long lasting release with possible increase of
antibiotic resistance [13, 14]. Due to these drawbacks and to the
widespread use of cementless implants in orthopedic and trau-
ma surgery, the attention is gradually shifting towards alterna-
tive delivery devices, and considerable attention is now being
addressed to active biodegradable materials that offer the ad-
vantage of bioreabsorption, reducing reactions induced by for-
eign bodies and increasing total local release of the drugs [15].
Hydrogels represent promising and potential alternative
materials able to locally convey antibiotics and regulate bone
bacterial infections related to orthopaedic devices [16, 17].
The aim of the present study was to test the ability of an
antibacterial-loaded bioreabsorbable hydrogel coating, obtain-
ed by derivatization of low molecular weight hyaluronic acid
(HA) with poly-D,L-lactic acid (PDLLA) [18], to reduce
bacterial acute colonization in an animal model of intra-
operative high-load bacterial contamination of an implant.
Materials and methods
Hydrogel synthesis and characterization
The study was performed on a fully bio-absorbable patented
hydrogel (DAC®, Novagenit®, Mezzolombardo, Italy; Patent
no.: WO2010/086421 A1), recently CE marked, which is
provided as a sterile powder in a prefilled syringe to be
hydrated at the time of use. The reconstitution takes place in
minutes and only a few steps are sufficient to obtain a highly
adhesive hydrogel with a rheological viscosity of 150–
400 Pa·s ready to be easily spread on the surface of an
orthopedic implant by means of a specifically designed
spreader. According to product specifications, reconstitution
of the hydrogel can be carried out by mixing it with various
antibacterial compounds.
Vancomycin release studies
Release studies were performed with DAC® hydrogel loaded
with 2 % (w/v) of vancomycin. Briefly, approximately 210±
20 mg of hydrogel were homogeneously spread onto
sandblasted titanium disk (Adler Ortho Srl, Cormano-Milan,
Italy) having a diameter of 25 mm and the exact quantity was
determined by means of an analytical balance. The disks with
the applied hydrogel were then vertically placed into 50 ml
centrifuge tubes (Corning®,MA, USA) and covered with 6ml
of Dulbecco’s phosphate buffered saline (Sigma®, Milan,
Italy). Tightly closed centrifuge tubes were incubated at
37 %, 85 % RH without agitation. At defined intervals
(i.e. at two, four, eight and 24 hours) 1 ml samples were asepti-
cally taken, placed into 2 ml cryogenic tubes (Corning®, MA,
USA) and frozen at –20 °C until analysis. Sample volume was
immediately replaced by fresh, pre-warmed phosphate buffer in
order to keep the volume constant throughout the entire study.
Release data were calculated as follows: analytical raw data
(expressed as μg/ml) normalized to the instrumental standard
curve were multiplied with the total buffer volume (ml) used
for incubation in order to determine substance quantity (μg).
Since sample volume was replaced with fresh buffer in order
to keep the volume constant, and this unavoidably leads to a
gradual dilution, the overall quantity (in μg) for a given time
point was determined by adding to the analytically determined
amount the substance quantities removed in the previous
sampling points. Finally, the substance release was expressed
as the percentage of the total quantity initially loaded
(i.e. concentration of the substance inside the hydrogel
[μg substance/μg hydrogel] × quantity of hydrogel loaded on
the disc [μg]).
In vivo studies
The animal research protocols were approved by the Ethical
Committee of the Rizzoli Orthopedic Institute and by the
appropriate public authorities and carried out in accordance
with the European and Italian Law on animal experimentation.
The experiments included an in vivo evaluation of hydrogel
long-term histocompatibility, according to ISO 10993-6: 2009
standards and a test of its anti-infective capabilities in a model
of acute, high-load intra-operative bacterial contamination of
an intra-medullary implant.
Forty adult male New Zealand pathogen free rabbits (Harlan
Laboratories SRL, S.Pietro al Natisone, Udine), 2.7±0.2 kg
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b.w., were housed in individual cages and fed with a standard
pellet diet (Mucedola, Settimo Milanese, Milan, Italy) and
water ad libitum. The animals were divided into seven groups
as reported in Table 1. All surgical procedures were performed
under general anaesthesia induced by intramuscular injection
of 44 mg/kg ketamine (Imalgene 1000, Merial Italy S.p.A,
Assago-Milan, Italy) and 3 mg/kg xylazine (Rompun, Bayer
SpA, Milan, Italy). Anaesthesia was maintained with O2/air
(1/0.4 l/min) mixture and 2–2.5 % sevorane (Sevorane,
ABBOTT Srl, Latina, Italy).
Postoperatively, analgesic therapy was administered for
three days (0.1 ml/kg/day metamizole sodium; Farmolisina,
Ceva Vetem SpA, Monza-Brianza, Italy) and antibiotics were
administered differently according to experimental designs
(Table 1):
– Histocompatibility study: Group A (n =10) underwent
a systemic antibiotic therapy with i.m. injections of
0.6 ml/kg flumequil (Flumexil, FATRO SpA, Bologna,
Italy) for three days.
– Perimplant MRSA bone infection study: Groups 1–6
(n =5 for each group) underwent a systemic antibiotic
therapy with i.v. injections of 2 % vancomycin in two
subsequent administrations, namely, 0.8 ml at one hour
before MRSA inoculum and intramedullary nail implant
and 0.8 ml within 24 hour from the inoculums.
At the end of experimental times, animals were pharmaco-
logically euthanised with the intravenous administration of
1 ml of Tanax (Tanax, Hoechst Roussel Vet, Milan, Italy)
under general anaesthesia as previously reported.
Histocompatibility study
Under sterile surgical conditions in group A, parapattelar skin
incision was performed bilaterally onto femoral condyles,
anterior cruciate ligament was displaced and articular surface
was exposed. A small stab incision was then performed and
2.5-mm drill holes were created in the intercondylar region of
each femur. Through this aperture, a 16-gauge needle was
introduced to the medullary cavity and 0.5 ml of bone marrow
was aspirated. Subsequently 1 ml of DAC® hydrogel was
slowly injected in the right condyles while 1 ml of sodium
hyaluronate (HYALGAN®, 20 mg/2 ml Fidia Farmaceutici
SpA; Abano Terme, Padova, Italy) as control material was
injected in the left condyles. Finally, the defects created in the
intercondylar region were sealed with sterile bone wax to
prevent leakage of the injection (Knochenwachs, B Braun,
Aesculap AG & Co., KG, Tuttlingen, Germany) and wounds
were sutured in layers.
Twelve weeks after surgery, femurs were explanted and
during dissection the presence of clinical signs of inflamma-
tion, haematomas, oedema, or tissue reactions were macro-
scopically evaluated; also lymphatic draining district (poplite-
al and inguinal lymph nodes) was taken into consideration.
Cylindrical bone segments about 1-cm long were obtained
with an oscillating saw by femoral diaphyses. Distal femoral
epiphyses and cylindrical diaphysis segments were fixed in
4 % paraformaldehyde.
Acute intra-operative MRSA implant contamination study
The MRSA strain used in this study was originally isolated
from a patient suffering from chronic osteomyelitis and main-
tained in culture for several years. The procedure adopted to
isolate and characterize the antibiotic resistance of the MRSA
strain used has already been reported [10]. Briefly, the MRSA
inoculum was prepared from overnight cultures grown in
Mueller Hinton Broth (MHB) starting from a frozen batch
at –80 °C and aliquots were prepared. The cells were
harvested by centrifugation, washed with saline solution
and resuspended in order to obtain a final density of
5x106 or 5×104 colony-forming units (CFU)/ml of MHB,
respectively. The MRSA inocula were stored at 4 °C and
used within 12 hours of preparation. The density and purity of
each bacterial preparation were verified before the surgical
Table 1 In vivo experimental
set-up Group N Treatment Experimental time
Histocompatibility evaluation
A 10 Right Femur Left femur 12 weeks
DAC hydrogel Sodium hyaluronate
Perimplant MRSA bone infection study
MRSA inoculum in right femur Treatment
1 5 High load (106 CFU) 0 % Vancomicyn-loaded DAC® 7 days
2 5 2 % Vancomicyn-loaded DAC®
3 5 5% Vancomicyn-loaded DAC®
4 5 Low load (104 CFU) 0 % Vancomicyn-loaded DAC®
5 5 2 % Vancomicyn-loaded DAC®
6 5 5% Vancomicyn-loaded DAC®
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session by performing colony counts on selective media after
plating on horse blood agar. The number of colonies in each
plate was counted by a blinded operator and the bacterial
concentration was determined.
Under sterile surgical conditions, a small stab incision and a
progressively larger drill hole up to 3.5 mm in diameter was
created in the intercondylar region of the right femur of each
rabbit. Subsequently, a 18-gauge needle was inserted until the
medullary cavity and 0.2 ml of bacterial suspension, containing
106 or 104 CFU of MRSA respectively, was directly inoculated
according to the experimental group reported in Table 1. Im-
mediately after inoculation, sandblasted titanium nails (Adler
Ortho Srl, Cormano-Milan, Italy), 3 mm in diameter and 40mm
in length with a surface roughness (Ra) of approximately 7 μm
(standard reference, Ra=5–9 μm) were coated directly by the
surgeon before implantation with DAC®hydrogel loaded with
0 %, 2 % or 5 % (w/v) vancomycin (Vancomycina Hospira
500 mg, Hospira SpA, Milan, Italy) respectively and implanted
through the same surgical access. Finally, the created defect in
the intercondylar region was filled with a small block of bone
wax (Knochenwachs, B Braun, Aesculap AG & Co., KG,
Tuttlingen, Germany) to avoid bacterial inoculums and hydro-
gel spilling out.
Seven days after surgery, under general anaesthesia, the
animals were submitted to 20 ml intracardiac blood sampling
for aerobic and anaerobic cultures (BacT/ALERT® 3D,
BioMérieux, Marcy l’Etoile, France). After euthanasia and
under sterile surgical conditions, the right femurs of each
rabbit were explanted, and the intramedullary nails were
removed in order to perform a swab of the femurs for
microbiological analysis. Thereafter, a diaphyseal cortical
segment of approximately 1 cm was obtained for further
microbiological investigations.
Histological and histomorphometric investigation
Bone samples retrieved by group A were immediately
dehydrated and finally embedded in amethylmethacrylate resin
solution (Merck Schuchardt OHG, Hohenbrunn, Germany).
Transverse sections of femoral diaphysis were obtained by
using rotative microtome (Leica SP1600, Leica Microsystems
SpA, Milan, Italy), while an automatic cutting grinding system
(EXAKT, EXAKT Apparatus GmbH, Norderstedt, Germany)
was used to obtain longitudinal sections of femoral epiphysis.
The obtained sections were then ground and polished to
20±10 μm thickness and finally stained with toluidine blue,
acid fuchsin and fast green.
All histological sections were digitized adopting Aperio
ScanScope CS System (Aperio Technologies, Vista, CA,
USA) at full resolution (1781×1467 pixels). Longitudinal
epiphyseal sections were used to perform a qualitative histo-
logical evaluation of cellular or tissue alterations related to
Fig. 1 Release of vancomycin from DAC® hydrogel at defined intervals
during incubation at 37 °C. Release expressed as percentage of total
antibiotic quantity loaded
Fig. 2 Histological images of
femoral distal epiphyses (a , b)
and cortical diaphyses (c , d)
treated with DAC® (a , c) and
control (b , d) hydrogel
(HYALGAN®) at a magnification
of 0.5x (a , b) and 5x (c , d).
Toluidine blue, acid fuchsin and
fast green
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DAC® hydrogel or HYALGAN® control material injection.
Instead, sections related to femoral mid-diaphysis were used
to perform histomorphometric investigations by means of the
image analysis system Leica Qwin (Leica Microsystems Ltd).
The following histomorphometric parameters were evaluated
onto sections:
– Diaphyseal sectional area (Se.Ar, mm²): area of the sec-
tion comprising the diaphyseal portion of cortical bone
tissue and the medullary area
– Medullary area (Me.Ar, mm²): cross-sectional area of the
diaphyseal medullary cavity
– Cortical area (Ct.Ar, mm²): total area of cortical bone
obtained by applying the following formula: Se.Ar-
Me.Ar
– Cortical bone thickness (mm): distance between the end-
osteal and periosteal surface of the cortical bone mea-
sured in ten different points distributed onto the entire
diaphyseal section
Microbiological investigations
Microbiological investigations were carried out on specimens
collected by groups 1 to 6. The blood culture procedure was
performed following a previously reported standard protocol
[19]. The microbiological investigations were performed
within two hours. Briefly, 1 ml of MHB was added to
each swab while the diaphyseal cortical segments and the
intramedullary nails were individually placed into 3 ml of
antibiotic free MHB. All samples were then agitated for
three minutes on a vortex to resuspend collected bacteria.
At the end of this procedure, a serial ten-fold dilution of
each suspension, i.e. from swabs and cortical bone seg-
ments, was prepared to determine the bacterial load. Brief-
ly, 10 μl of each dilution was plated onto horse blood
agar and incubated at 37 °C for 48 hours. At the end of
the incubation period the number of MRSA colonies on
each plate was counted and the total viable CFU load was
determined and expressed as log CFU/ml.
Statistical analysis
Statistical evaluation of data was performed using the soft-
ware package SPSS 12.1 (SPSS Inc., Chicago, IL USA). Data
are reported as median (min-max) at a significance level of
p <0.05. After having verified the normal distribution and the
homogeneity of the variance, the non-parametric Kruskal-
Wallis test, followed by the Monte Carlo methods to compute
probability, was used to analyse data. Then, Mann-Whitney U
was performed to detect significant differences between
groups by adopting Bonferroni correction.
Results
Release studies
The functionality of DAC® hydrogel to efficaciously and
efficiently release previously loaded vancomycin was deter-
mined in vitro.
As shown in Fig. 1, release studies carried out on three
distinct production batches of DAC® product demonstrated
that already after two hours from incubation start approxi-
mately 40% of the overall vancomycin quantity were released
into the surrounding solution reaching more than 80 % within
the first 24 hours.
Table 2 Histomorphometric results of cortical bone parameters of group









Se.Ar (mm²) 166.99±25.74 170.26±28.75
Me.Ar (mm²) 88.78±17.38 91.97±25.90
Ct.Ar (mm²) 78.21±15.75 78.29±13.47
Ct.Th (mm) 2.15±0.54 2.01±0.41
Se.Ar sectional area, Me.Ar medullary area, Ct.Ar cortical area, Ct.Th
cortical thickness
Table 3 Microbiological results of blood expressed as CFU/ml of 0 %, 2 % and 5 % (w/v) vancomycin-loaded DAC® treated groups for both MRSA
bacterial loads (104 or 106 CFU): median (min-max), n =5
Group MRSA load Treatment Median (Min – Max)
1 High load (106 CFU) 0 % Vancomicyn-loaded DAC® 1.00E+07 (0.00E+00 – 1.00E+07)
2 2 % Vancomicyn-loaded DAC® 0.00E+00
3 5% Vancomicyn-loaded DAC® 0.00E+00
4 Low load (104 CFU) 0 % Vancomicyn-loaded DAC® 5.00E+03 (0.00E+00 – 5.00E+03)
5 2 % Vancomicyn-loaded DAC® 0.00E+00
6 5% Vancomicyn-loaded DAC® 0.00E+00
Mann-Whitney U test: group 2 (p =0.032) and group 3 (p =0.032) versus group 1, and group 5 (p =0.009) and group 6 (p =0.024) versus group 4
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Histocompatibility study
Neither inflammatory nor degenerative signs were found in
femoral segments and joint surfaces at the retrieval. The
observation of popliteal and inguinal lymph nodes showed
no signs of swelling or morphological alteration due to
inflammatory or degenerative processes. No differences in
the structural organization of bone tissue between segments
treated with DAC® and control hydrogel were observed
(Fig. 2). The histomorphometric evaluations showed no sta-
tistically significant differences between DAC® and control
hydrogel for all parameters evaluated (Table 2), confirming
the qualitative evaluation.
Perimplant MRSA bone infection study
All the animals tolerated surgery and the post-operative period
well. Microbiological investigations showed high bacterial
load in blood cultures taken in control animals, while blood
cultures of vancomycin-loaded hydrogel groups were all
negative (Table 3) (p <0.05).
Intra-medullary swabs (Table 4) and bone microbiological
samples (Table 5) were positive for MRSA at one week from
surgery ranging from 103 to 108 CFU/ml. In groups 1 and 4, in
which antibiotic-free DAC® hydrogel was applied together
with a high (106) or lower (104) MRSA inoculum, respectively,
bacterial contamination increased up to more than 108 in group
1 and 105 CFU in group 4 after one week from surgery, even in
the presence of vancomycin administered systemically. On the
contrary in groups 2 and 3, application of DAC® hydrogel
loaded with 2 % or 5 % (w/v) of vancomycin, respectively, in
the presence of a highMRSA inoculum (i.e. 106 CFU) resulted
in a significant (p <0.05) inhibition of MRSA growth at both
antibiotic concentrations (2% and 5%), reducing the local load
in all the sites of investigation by about 99 % in comparison to
group 1. Similar results were obtained for groups 5 and 6 in
comparison to group 4 where, in the presence of a lower
(104 CFU) MRSA load, significant (p <0.05) reductions were
achieved by the application of vancomycin loaded DAC®
hydrogel: 72–90 % for intramedullary swabs in groups 5 and
6, respectively.
Discussion
Biofilm-related infections are among the main reasons for
failure of joint prosthesis with high associated social and
economical costs [20, 21], often requiring challenging diag-
nosis and prolonged and complex treatments [22–24].
Although antibacterial coatings have been proposed to pre-
vent bacterial colonization and biofilm formation, available
technologies are far from large scale application, due to various
limitations, including questionable long-term effect on bacterial
resistance, osteointegration, regulatory issues and costs [25, 26].
Table 4 Microbiological results of intramedullary swab expressed as CFU/ml of 0 %, 2 % and 5 % (w/v) vancomycin-loaded DAC® treated groups for
both MRSA bacterial loads (104 or 106 CFU): median (min-max), n =5
Group MRSA load Treatment Median (Min – Max)
1 High load (106 CFU) 0 % Vancomicyn-loaded DAC® 1.00E+08 (7.40E+05 – 1.07E+08)
2 2 % Vancomicyn-loaded DAC® 5.00E+04 (7.40E+03 – 8.40E+04)
3 5% Vancomicyn-loaded DAC® 4.80E+04 (8.80E+03 – 8.40E+04)
4 Low load (104 CFU) 0 % Vancomicyn-loaded DAC® 5.00E+05 (3.20E+04 – 5.00E+05)
5 2 % Vancomicyn-loaded DAC® 1.40E+04 (5.00E+03 – 3.90E+04)
6 5% Vancomicyn-loaded DAC® 4.90E+03 (2.80E+03 – 5.00E+04)
Mann-Whitney U test: group 2 (p =0.012) and group 3 (p =0.009) versus group 1; Group 5 (p =0.027) and group 6 (p =0.048) versus group 4
Table 5 Microbiological results of cortical bone expressed as CFU/ml of 0 %, 2 % and 5 % (w/v) vancomycin-loaded DAC® treated groups for both
MRSA bacterial loads (104 or 106 CFU): median (min-max), n=5
Group MRSA load Treatment Median (Min – Max)
1 High load (106 CFU) 0 % Vancomicyn-loaded DAC® 1.00E+08 (6.50E+05 – 1.00E+08)
2 2 % Vancomicyn-loaded DAC® 5.90E+04 (7.20E+03 – 8.70E+04)
3 5% Vancomicyn-loaded DAC® 4.80E+04 (7.90E+03 – 9.50E+04)
4 Low load (104 CFU) 0 % Vancomicyn-loaded DAC® 5.00E+05 (4.50E+05 – 7.80E+05)
5 2 % Vancomicyn-loaded DAC® 4.60E+05 (3.50E+05 – 6.70E+05)
6 5% Vancomicyn-loaded DAC® 1.90E+04 (8.00E+02 – 4.40E+04)
Mann-Whitney U test: group 2 (p =0.009) and group 3 (p =0.012) versus group 1; group 6 versus group 4 (p =0.009) and group 5 (p =0.012)
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A first aim of the present study was to provide further
analysis concerning histocompatibility of DAC® hydrogel
that already met ISO standards, according to previous studies
(Novagenit SRL, data on file); in this regard, the present
research shows no long-term effect of DAC® hydrogel on
bone tissue.
A second aim was to evaluate the antibacterial effect of the
hydrogel, in combinationwith vancomycin in an animal model.
In line with previous observations that bacterial adhesion and
subsequent biofilm formation develop within hours after
biomaterials implant into the human body, when a “race
to the surface” takes place between the host’s cells and the
colonizing bacteria eventually present at the surgical site
[12, 27–29], this study provides evidence that local appli-
cation of a resorbable hydrogel coating and a fast local
delivery of antibiotics is effective in significantly reducing
bacterial colonization of intra-medullary cavity and bone in
an animal model. Current data show that, in the presence
of high load bacterial contaminations (106 and 104), as
used in this study, even targeted systemic prophylaxis is
not able to prevent local infection or systemic spreading of
bacteria in a model of implant-related infection in a not-
immunocompromised host. Local antibacterial coating did,
on the other hand, completely abolish haematogenous
spreading of bacteria after local inoculums and dramatically
reduced the bacterial load at the bone/implant interface.
This study has some limits:
– The antibacterial effect was studied with one bacterial
strain, that, although a typical pathogen of implant-
related infection, may not be representative of other
microorganisms’ susceptibility to the coating;
– The bacterial load used in this study was high and may
not reflect the clinical setting, where much lower bacterial
contamination is expected, at least in clean surgery. How-
ever, it may be speculated that the protective action of the
coating may still be more beneficial to prevent implant
colonization in the presence of lower contamination;
– Only two concentrations of vancomycin were tested.
Although a small dose-dependent effect was observed,
no final conclusion may be drawn on the basis of the
present study as to regard the best antibiotic concentration
to be used in the hydrogel, while other antibacterial drugs
may be more indicated, in particular, cases in the clinical
setting;
– This study focused on acute colonization of an implant,
and data were collected after seven days from surgery.
Long-term efficacy of the hydrogel on the colonizing
pathogens was not investigated in the present study. A
long-term study in rabbits at 28 days is on-going.
In conclusion, the present study provides evidence for the
first time that DAC®, a resorbable hydrogel coating, composed
of covalently linked hyaluronan and poly-D,L-lactide,
which can be hydrated with different antibacterial com-
pounds (vancomycin, tobramycin, gentamicin, meropenem,
levofloxacin, linezolid, daptomycin, N-acetylcysteine, etc.)
is able to quickly deliver vancomycin locally. Vancomycin-
loaded DAC® coating significantly reduces acute local and
systemic bacterial count following high local MRSA con-
tamination of an intra-medullary nail, in an animal model,
without detectable side effects. Moreover, DAC® hydrogel
long-term histocompatibility with bone tissue has been
shown. Antibacterial-loaded DAC® coating may represent
a possible option to protect orthopaedic implants from
bacterial colonization, provided that further studies will
confirm its efficacy in vivo and in the clinical setting.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
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